Award type :
Product Development Award (Bridging Award)
Product Development Award (Bridging Award)
Product type :
Vaccines
Vaccines
Award year :
2022
2022
Project start date :
05 / 04 / 2022
05 / 04 / 2022
Project end date :
05 / 31 / 2024
05 / 31 / 2024
Project duration (months) :
24
24
Development stage :
Phase 1
Phase 1
Linked Project :
Cholera Conjugate Vaccine
Cholera Conjugate Vaccine
Target disease :
Cholera
Cholera
Region served :
Sub-Saharan Africa
Sub-Saharan Africa
Recipient organization / Country of funding recipient organization :
International Vaccine Institute (IVI) / Republic of Korea
International Vaccine Institute (IVI) / Republic of Korea
Collaborator(s) / Country :
EuBiologics / Republic of Korea, Massachusetts General Hospital (MGH) / USA
EuBiologics / Republic of Korea, Massachusetts General Hospital (MGH) / USA
Funding amount(KRW) :
2,642,828,555
2,642,828,555
This project continues on from the previously awarded grant from development to the production of the cGMP-compliant materials in several formulations for the phase I clinical trial evaluation. This project is a successful case of materializing the technology transfer of a cholera conjugate vaccine (CCV) product from Massachusetts General Hospital (MGH) to EuBiologics. The completion of the phase I first-in-human (FIH) study within this project period will generated key information on product safety and effects of various antigen doses to guide dose selection.